Highest-materiality recent filing
Solid Biosciences upsizes ATM equity facility to $200M; $85M already sold
Filed prospectus supplement for up to $200M in common stock sales under existing ATM agreement with Jefferies.
Solid Biosciences shareholders approve doubling of authorized common stock to 480M
Approved charter amendment increasing authorized common shares from 240M to 480M; filed June 10, 2026.
Ilan Ganot resigned from Class III effective 4:00 p.m. ET on April 10, 2026.
40 participants dosed; SGT-003 well tolerated with steroid-only immunomodulation regimen.
Solid Biosciences raises ~$240M in private placement; prelim cash ~$188M
Gross proceeds ~$240M from 14.97M shares at $5.61 and 27.81M pre-funded warrants at $5.609.
Cash, cash equivalents and available-for-sale securities: $236.1M as of Sep 30, 2025; runway into H1 2027.
SLDB stockholders approve doubling authorized shares to 240M and adding 9M shares to equity plan
Authorized common stock increased from 120M to 240M via Certificate of Amendment filed June 12, 2025.
Solid Biosciences ups ATM offering capacity to $85M; $10.5M already sold
Filed prospectus supplement on May 15, 2025 to increase ATM offering from $75M to $85M.
Solid Biosciences reports 110% avg microdystrophin expression from SGT-003 Phase 1/2 trial
First three participants showed average 110% microdystrophin expression by western blot and 78% dystrophin-positive fibers at Day 90.
Solid Biosciences prices $200M underwritten offering; extends cash runway into first half 2027
Priced $200M underwritten offering expected to close Feb 19, 2025; net proceeds to fund R&D for SGT-003 and other candidates.
Solid Biosciences prices $200M public offering of common stock and pre-funded warrants
Priced public offering of 35.7M shares at $4.03/share and pre-funded warrants for 13.9M shares at $4.029 each; gross proceeds ~$200M.
Adam Koppel and Rajeev Shah resigned from the Board effective June 11, 2024; no disagreement cited.
Solid Biosciences raises $108.9M in private placement; preliminary cash $123.9M
Gross proceeds ~$108.9M from 16,973,103 shares at $5.53/share and 2,712,478 pre-funded warrants at $5.529 each.
Solid Biosciences gets FDA IND clearance for Duchenne gene therapy SGT-003; Phase 1/2 trial planned
FDA clears IND for SGT-003, a next-generation microdystrophin gene therapy for Duchenne muscular dystrophy.
Solid Biosciences stockholders elect four Class II directors, ratify auditor, approve ESPP amendment
Elected Clare Kahn, Adam Koppel, Adam Stone, Lynne Sullivan as Class II directors to 2026; votes ranged 13.6M–14.2M for, 76K–664K withheld.
Carl Morris resigns as CSO Neuromuscular; Jennifer Marlowe to become CSO
Carl Morris resigns as Chief Scientific Officer, Neuromuscular, effective July 14, 2023.
Solid Biosciences presents one-year IGNITE DMD data; SGT-001 program concluded
One-year data: mean 69.8% normal dystrophin by Western blot in 2E14 vg/kg cohort (Pt.5 at 18 months).
Solid Biosciences holds less than $1M at Silicon Valley Bank; no material exposure
Cash balance at SVB is de minimis (<$1.0M) per March 13, 2023 filing.
Solid Biosciences appoints Kevin Tan CFO, discloses $214M cash, targets SGT-003 IND in H2 2023
Kevin Tan appointed CFO effective Jan 9, 2023; base salary $425k, 40% bonus target, equity grants.
Solid Biosciences closes AavantiBio acquisition, $75M PIPE, Bo Cumbo named CEO
Issued 1,354,258 shares of common stock plus $1,000 cash to AavantiBio equityholders upon close.
Solid Biosciences stockholders approve share issuance for AavantiBio merger and amended equity plan
Stockholders approved issuance of shares for the acquisition of AavantiBio under the Merger Agreement (4,054,470 for, 41,480 against).
Solid Biosciences effects 1-for-15 reverse stock split, reduces authorized shares to 60M
1-for-15 reverse stock split effective Oct. 27, 2022; trading on split-adjusted basis begins Oct. 28.
Solid Biosciences acquires AavantiBio in stock deal, raises $75M PIPE, appoints new CEO
Acquires AavantiBio for 15% of SLDB common stock plus $1,000; AavantiBio lead program in Friedreich's Ataxia gene therapy.
Solid Biosciences to acquire AavantiBio; announces $75M private placement
Merger: Solid acquires AavantiBio through transitory subsidiary merger; AavantiBio survives as wholly owned.
Solid Biosciences reports Q2 net loss $25.1M; cash runway into Q2 2024; SGT-003 IND on track
Net loss $25.1M in Q2 2022 vs $18.7M in Q2 2021; collaboration revenue $6.2M (up from $3.6M).
Solid Biosciences stockholders approve reverse stock split and authorized share increase
Elected Class I directors Huffines, Nagendran, Shah with ~65.9M votes each.
Solid Biosciences receives Nasdaq deficiency notice for bid price below $1.00
Received deficiency letter on May 31, 2022 for failing to meet $1.00 minimum bid price requirement over 30 consecutive business days.
Solid Biosciences restructures, cuts 35% of staff; Q1 net loss $25.3M; COO resigns
Headcount reduced ~35% to align resources behind SGT-001 and SGT-003; cash runway extended into Q2 2024.
Solid Biosciences board adopts new Code of Business Conduct and Ethics
Board approved new Code of Business Conduct and Ethics on March 30, 2022.
Solid Biosciences reports $210M cash, advances DMD gene therapies; names Ian Smith Executive Chair
Preliminary, unaudited cash and investments of ~$210M as of Dec 31, 2021.
Solid Biosciences reports improved pulmonary function in DMD gene therapy trial, controls decline
PEF % predicted improved in all 4 evaluable dosed patients (+2.5% to +38.5%); 2 evaluable controls declined (-1.1%, -18.2%) at one year.
Corrected 1.5-year FVC change for patient five: +22.5% (previously reported incorrectly).
Solid Biosciences reports SGT-001 1.5-year data showing functional benefit in DMD patients 4-6
NSAA mean decrease 1.7 pts vs expected 4.5 pt decline from natural history; difference +2.8 pts.
Solid Biosciences Q2 net loss $18.7M; cash $249M; next IGNITE DMD dose in Q4 2021
Collaboration revenue of $3.6M vs $0 in prior year from Ultragenyx deal.
Adam Koppel notified Solid Biosciences Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), effective as of June 11, 2024.
Rajeev Shah notified the Company of his decision to resign as a member of the Board, effective as of June 11, 2024.
Following the Separation Date, Jennifer Marlowe, Chief Scientific Officer, Friedreich’s Ataxia and Cardiac Pipeline of the Company, will assume Dr. Morris’ responsibilities and serve as Chief Scientific Officer of the Company.
On May 22, 2023, Solid Biosciences Inc. (the “Company”) and Carl Morris entered into an executive transition and separation agreement (the “Separation Agreement”) providing for Dr. Morris’ resignation as Chief Scientific Officer, Neuromuscular of the Company.
On January 6, 2023, the Company’s Board of Directors (the “Board”) appointed Kevin Tan as the Company’s Chief Financial Officer, effective as of January 9, 2023
In connection with Mr. Tan’s appointment, Stephen DiPalma, the Company’s Interim Chief Financial Officer and principal financial officer and principal accounting officer, will cease to serve in such roles, effective as of the Appointment Date.
Erin Powers Brennan notified the Company of her resignation as the Company’s Chief Legal Officer and Secretary
Ilan Ganot notified the Company of his resignation as the Company’s Chief Executive Officer and President
On November 30, 2022, the Board also elected Adam Koppel, M.D., Ph.D., as a member of the Board, subject to and contingent and effective upon the closing of the Acquisition.
On November 30, 2022, the Board appointed Alexander (Bo) Cumbo as the Company’s President and Chief Executive Officer and elected Mr. Cumbo as a member of the Board, in each case, subject to and contingent and effective upon the closing of the Acquisition (the “Effective Date”).
On September 29, 2022, Erin Powers Brennan also notified the Company of her intention to resign as the Company’s Chief Legal Officer and Secretary, subject to, and contingent and effective upon, the Effective Date.
On September 29, 2022, the Company entered into an employment agreement with Alexander Cumbo (the “Cumbo Employment Agreement”), pursuant to which Mr. Cumbo will serve as the Company’s President and Chief Executive Officer, subject to his appointment to such position by the Board and subject to, and contingent and effective upon, the Effective Date.
Max materiality 0.85 · Median 0.62 · Most common event other_material